Natera said it is expanding beyond its existing MRD footprint after a series of regulatory milestones for Signatera. The company received FDA approval for companion diagnostic use in muscle-invasive bladder cancer, was included in NCCN guidelines for the same indication, and also secured Japan PMDA approval for colorectal cancer. Natera further cited Europe IVD regulation certification for Signatera across multiple cancers, giving it a platform to scale MRD testing beyond initial markets. Chief medical officer Alex Aleshin described Japan colorectal cancer demand as a key driver, noting that reimbursement discussions are still under way. With the company preparing to broaden MRD presence and enter early cancer detection, the regulatory sequence underscores how liquid biopsy adoption increasingly depends on multi-jurisdiction approvals and guideline inclusion rather than single-indication data alone.